Although scientists are still probing how biglycan influences bone formation, the protein may prove an attractive target for
possible osteoporosis drugs, says John Termine, a specialist on the disease at Lilly Research Laboratories in Indianapolis.
For most of us — including Mullin — the
possible benefits of taking a weight - loss
drug, off - label or not, usually do nt justify the risks, which can include
osteoporosis and more (see «Off - Label
Drugs» below).